Langenberg, Karin P.S.; van Hooff, Sander R.; Koopmans, Bianca; Strijker, Josephine G.M.; Kholosy, Waleed M.; Ober, Kimberley; Zwijnenburg, Danny A.; van der Hoek, Jessica J.F.; Keller, Kaylee M.; Vernooij, Lindy; Schild, Linda G.; Looze, Eleonora J.; Ebus, Marli E.; Essing, Anke H.W.; Vree, Paula de; Tas, Michelle L.; Matser, Yvette A.H.; Wienke, Judith; Volckmann, Richard; Tops, Bastiaan B.J.; Kester, Lennart A.; Badloe, Shashi; Hehir-Kwa, Jayne Y.; Kemmeren, Patrick; Goemans, Bianca F.; Zwaan, C. Michel; Oehme, Ina; Jäger, Nathalie; Witt, Olaf; van Eijkelenburg, Natasha K.A.; Dierselhuis, Miranda P.; Tytgat, Godelieve A.M.; Wijnen, Marc H.W.; van Noesel, Max M.; de Krijger, Ronald R.; Eising, Selma; Koster, Jan; Dolman, Emmy M.; Molenaar, Jan J.
(Elsevier Limited, 2025-03-11)
Introduction: Despite druggable events to be present in 80 % of neuroblastomapatients within the Princess Máxima Center precision medicine program 'iTHER', clinical uptake of treatment recommendations has been low, and the ...